))
17. Democratizing Drug Discovery: How Lilly ExploR&D Is Changing the Biotech Playbook
Manage episode 522519934 series 3662745
The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships on terms controlled by Big Pharma. Tom Hopkins, VP and Head of Lilly ExploR&D, is working to flip that script.
In this episode, Tom joins your host Mike Ward to discuss the four critical barriers early-stage biotechs face (expertise gaps, data infrastructure challenges, execution risk, and capital inefficiency) and how Lilly's integrated platform of capital, expertise, and infrastructure is removing those barriers.
Learn how the future of drug discovery isn't about companies innovating in isolation, it's about removing friction and accelerating the best science from wherever it exists toward patients.
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)
Chapters
1. The Problem: Access To Top R&D (00:00:00)
2. Tom’s Journey And Motivation (00:01:14)
3. Catalyze 360: The Four Pillars (00:03:30)
4. Real-World Example Of Acceleration (00:05:15)
5. Today’s Biotech Headwinds (00:06:27)
6. Operator Insights Vs Consultants (00:08:21)
7. Vendor Network And Time Savings (00:09:36)
8. AI Reality For Early Biotechs (00:10:42)
9. Federated Learning With TuneLab (00:12:10)
10. Operating Model And Engagement (00:13:01)
11. Pricing, Speed, And Risk Sharing (00:14:21)
12. Balancing Collaboration And IP (00:15:42)
13. Breadth Beyond Lilly’s Focus (00:16:44)
14. Case Studies And Super Users (00:17:42)
15. Trends: AI In Development (00:18:10)
16. Practical Next Steps For Teams (00:19:00)
17. What Energises The Team (00:20:04)
18. Closing Thoughts And Resources (00:21:00)
17 episodes
Share
